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Abstract
Background: Although the graft-versus-tumor (GVT) effect of donor-derived T cells after allogeneic hematopoietic
stem cell transplantation has been used as an effective adoptive immunotherapy, the antitumor effects of cord
blood (CB) transplantation have not been well studied.
Methods: We established the animal model by transplantation of CB mononuclear cells and/or tumor cells into
NOD/SCID mice. The presence of CB derived T cells in NOD/SCID mice or tumor tissues were determined by flow
cytometric and immunohistochemical analysis. The anti-tumor effects of CB derived T cells against tumor was
determined by tumor size and weight, and by the cytotoxicity assay and ELISPOT assay of T cells.
Results: We found dramatic tumor remission following transfer of CB mononuclear cells into NOD/SCID mice with
human cervical tumors with a high infiltration of CD3
+ T cells in tumors. NOD/SCID mice that receive neonatal CB
transplants have reconstituted T cells with significant antitumor effects against human cervical and lung tumors,
with a high infiltration of CD3
+ T cells showing dramatic induction of apoptotic cell death. We also confirmed that
T cells showed tumor specific antigen cytotoxicity in vitro. In adoptive transfer of CD3
+ T cells into mice with
pre-established tumors, we observed much higher antitumor effects of HPV-specific T cells by ELISPOT assays.
Conclusions: Our results show that CB derived T lymphocytes will be useful for novel immunotherapeutic
candidate cells for therapy of several tumors in clinic.
Background
Human umbilical cord blood (CB) has been used suc-
cessfully as an alternative to allogeneic bone marrow for
hematopoietic reconstitution in various hematological
disorders. This clinical application is used because CB is
readily available and has a rich source of hematopoietic
stem cells with highly proliferative capacities [1-3].
There are some reports that CB is composed of pheno-
typically and functionally immature cytotoxic T lympho-
cytes (CTLs) with decreased alloantigen-specific
cytotoxicity. In comparison to CTLs in peripheral blood,
the CTLs derived from cord blood show a high expres-
sion of CD45RA (a naïve T cell marker) and a low
expression of CD45RO (an activated T cell marker)
[4-7]. However, CB-T cells have more polyclonal
diversity in complementarity of determining region 3
(CDR3) of the T cell receptor (TCR) than adult T cells,
which have a more monoclonal profile due to a selec-
tion process in the thymus [8,9]. Immunotherapy with
infusion of donor lymphocytes after allogeneic hemato-
poietic stem cell transplantation has recently provided
an effective means of augmenting the graft-versus-
tumor (GVT) response to a variety of tumors [10-13].
Adoptive T cell transfer from allogeneic and autologous
sources can augment the regression of tumors and viral
infections. These T cells are specific to tumor antigens
and retain their ability to proliferate, thus maintaining
their effector function and homing abilities in vivo
[10,14]. In humans, T cell therapy for cancer has been
conducted with peripheral blood, tumor infiltrating lym-
phocytes (TIL), and lymph nodes. The bone marrow of
patients with breast cancer contained CD8
+ T cells with
specificity for tumor-associated antigens. The adoptive
transfer of these cells into mice with xenografted tumor
* Correspondence: dokukim@konkuk.ac.kr
3Department of Animal Biotechnology, Konkuk University, Seoul, Republic of
Korea
Full list of author information is available at the end of the article
Lee et al. BMC Cancer 2011, 11:225
http://www.biomedcentral.com/1471-2407/11/225
© 2011 Lee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.caused tumor regression and necrosis, as well as tumor-
cell apoptosis [14].
Cervical cancer is the second most common female
malignancy worldwide and remains a clinical problem
despite improvements in early detection and therapy
[15,16] In addition, lung cancer is the leading cause of
cancer mortality, even several aggressive treatments with
surgery, radiation, and chemotherapy, the long-term survi-
val remains still low [17]. There are several trials that
effective immune-based anti-tumor therapy has been tried
with cytokines, passive and active immunotherapeutic
methods, such as INF-a, antibodies, dendritic cells, and T
cells, including tumor antigens [18-20]. In addition,
immune cells from cord blood, such as dendritic cells, NK,
and LAK cells have been studied as anti-tumor therapeutic
cells [21-24]. However, it is still not clear whether CB T
cells have immunotherapeutic antitumor activity.
Here, we show that human T cells from CB have anti-
tumor activities in mice bearing a model of human cer-
vical and lung tumor. In these mice, tumor tissue was
highly infiltrated with CB-T cells. Subsequently, we
found that CB-T cells that were reconstituted in NOD/
SCID mice retained the ability to proliferate and differ-
entiate. We subsequently demonstrated dramatic, speci-
fic cytotoxicity against tumor cells in CB-T pre-
reconstituted animal model. In addition, adoptive T cell
transfer exerted a strong antitumor activity in NOD/
SCID mice with pre-established tumors. In addition, the
transferred T cells had antigen-specific binding to HPV.
In summary, cord blood may be used for stem cell
reconstitution and immunotherapy for a variety of
hematopoietic disorders and solid tumors.
Methods
Primary cells and cell lines
Human cord blood samples were approved by the insti-
tutional review board and obtained from umbilical and
placental tissues according to the institutional guidelines
of CHA General Hospital. Mononuclear cells from CB
were isolated by density gradient centrifugation in
Ficoll-Paque™ Plus (Amersham Biosciences, Sweden).
Purified cells were washed and suspended in phosphate-
buffer saline (PBS) containing 2% of fetal bovine serum
(FBS). After washing two times, cells were placed on ice
until transplantation into NOD/SCID mice. Caski, HeLa,
and A549 cell lines were purchased from Korean Cell
Line Bank (KCLB) and cultured at 37°C, 5% CO2 in
RPMI 1640 media, supplemented with EMEM, 10%
heat-inactivated FBS, penicillin/streptomycin (50 U/ml),
L-glutamine (300 mg/L), HEPES (25 mg/L).
Mice and cord blood transplantation
NOD/Shi-scid (NOD/SCID) mice purchased from the
Animal Laboratory of KKIBB of Korea were bred and
maintained in an animal facility at the CHA Stem Cell
Institute at Pochon CHA University. The mice were
kept in microisolator cages and given autoclaved food
and water. To reconstitute T cells in these NOD/SCID
mice, we injected 1 × 10
7 CB mononuclear cells intra-
peritoneally when the mice were 1-3 days old. To estab-
lish the human cervical tumor animal model, 2 × 10
6
cervical cancer (Caski or HeLa cells) and lung cancer
(A549) cells were injected subcutaneously into the pos-
terior flanks of 6-10 week-old NOD/SCID mice. To
determine the antitumor effects of CB mononuclear
cells, 1 × 10
7 of these cells were injected into the tumor
site, either at the same time or 14 days after an injection
of Caski tumor cells. Tumors became visible and palp-
able within 2 weeks after the injection of the tumor
cells. Tumor growth was measured with calipers every
week. The final volume and weight of the tumors were
determined when the animals were sacrificed 8 weeks
after the injection of tumor cells. All animal experiments
i nt h i ss t u d yw e r ea p p r o v e db yt h eC H AU n i v e r s i t y
Ethical Committee for Animal Experiment Regulation.
Flow cytometry analysis
When the mice were sacrificed, the bone marrow,
spleen, lymph nodes, thymus, and peripheral blood were
collected and stored in PBS containing 2% FBS. The tis-
sues were teased apart and passed through a nylon filter
to remove debris. Samples were prepared as single cell
suspensions in staining media with PBS and 2% FBS.
Cells were stained with the following labeled antibodies
(Abs): FITC-conjugated anti-human CD45 (HI30), CD4
(RPA-T4), TCRgδ (B1.1), CD45RO (UCHL1), CD45RA
(HI100); PE-conjugated anti-human CD34 (581), CD33
(WIM53), CD19 (HIB19), CD8 (HIT8a), TCRab
(T10B9.1A-31); APC-conjugated anti-human CD56
(B159), CD3 (UCHT1), CD14 (M5E2); and isotypic con-
trol Abs which were purchased from BD Pharmingen.
Stained cells were analyzed with the fluorescence-acti-
vated cell sorter (FACS) VantageSE flow cytometry (BD-
Biosciences). Data were live-gated by forward and side
scatter and lack of propidium iodide uptake. The fre-
quencies in quadrant corners are given as percentages of
gated cells.
Adoptive transfer of T cells in tumor animal model
To confirm tumor specific anti-tumor activity by prim-
ing T cells, NOD/SCID mice at 6 to 8 weeks of age
were used as hosts for models of human cervical cancer.
Before adoptive transplantation with purified T cells, 2
×1 0
6 Caski cells were inoculated subcutaneously into
the posterior flanks of the mice. Four weeks after this
injection, these mice were injected at the tumor site
with antitumor human CD3
+ T cells. These T cells were
isolated from splenocytes of NOD/SCID mice that had
reconstituted T cells injected with tumor cells for 8
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(2
nd CB-T cells) or not injected with any tumor cells,
called non-adapted T cells( 1
st CB-T cells) as control.
Single splenocytes were stained with FITC-conjugated
anti-human CD3 (UCHT1) antibody and purified with
the EasySep MACS purification kit (StemCell Tech), fol-
lowing the manufacturer’s instructions. Flow cytometry
w a su s e dt oc o n f i r map u r i t yo f9 5 %f o rt h e s ei s o l a t e d
human CD3
+ T cells. After twice washing with PBS, the
cells were injected into the tumor region of NOD/SCID
mice 4 weeks after Caski cell inoculation. Tumor size
and progression was monitored every week measure-
ments of tumors with calipers.
Immunofluorescence of tissues
Fresh tissues and tumors were rapidly frozen in Tissue-
Tek (Sakura Finetek). To visualize the presence of
human T cells, 7-μm frozen sections were fixed with
100% ethanol, directly stained for 1 h at room tempera-
ture with either FITC and PE anti-human- CD45(HI30),
CD4(RPA-T4), CD8(HIT8a), CD45RO(UCHL1), and
TCRab (BD Pharminogen) antibody. All sections were
counterstained with 1 μg/ml Hoechst 33342 (Sigma-
Aldrich) to visualize cell nuclei. After incubation with
antibodies, sections were washed twice, and analyzed by
immunofluorescence microscopy using an Apotome
(Carl Zeiss). Apoptotic cells were detected by the
TUNEL assay (Roche).
Cytotoxicity assay of T cells in vitro
For detection of specific antitumor cytotoxicity of T
cells, the cells were purified from splenocytes of NOD/
SCID mice with antitumor activity. The purification was
performed with the MACS isolation kit, and then the
purity determined to be at least 95% CD3
+ by flow cyto-
metry analysis. Caski cells and A549 cells, previously
labeled with retrovirus containing green fluorescent pro-
tein (GFP), were used as target cells and control cells,
respectively, at various effector:target ratios. Target cells
were incubated in a 96 well plate (5 × 10
4 cells/well)
with varying numbers of effector cells (hCD3 positive
cells). After 2 days of culture, we harvested whole cells,
stained them with Annexin V and propidium iodide,
and measured, by flow cytometry, the percentage of
Annexin V+ cells in gated GFP+ cells, as an indicator of
specific cytotoxicity. Results were expressed as the mean
of four replicates from the data, using CellQuest soft-
ware (BD Bioscience).
ELISPOT assay
To determine cervical tumor specific T cells responses
against cervical tumor, T lymphocytes that produced
IFN-g for specific HPV epitope peptides were identified
as described [16]. For induction of tumor specific
response, human CD3
+ T cells were selectively isolated
by MACS from splenocytes of NOD/SCID mice that
were either injected with Caski tumor cells 8 weeks
earlier or not injected with tumor cells (as a control). For
the induction of HPV specific reaction, peptides from
HLA-A2 restricted E7 peptides of HPV, E711-20 peptide
(YMLDLQPETT) and E786-93 peptide (TLGIVCPI), were
used as tumor antigens, and co-incubated with purified
CD3
+ T cells (1 × 10
5 /well) for 24 hr. The production of
IFN-g after in vitro stimulation with peptides was deter-
mined using the ELISPOT kit in accordance with the
manufacturer’s instructions (BD Biosciences).
Statistics
Statistical significance in the differences between experi-
mental groups was assessed by a two-tailed Student’s t
test. The data are expressed as means ± SD. In all fig-
ures, multiple comparisons were made with Bonferroni
adjustment to calculate p levels of significance. Statisti-
cal significance was determined at the level of P < 0.05.
Results
Anti-tumor effects by cord blood mononuclear cells in
human tumor model
In comparison to T cells in peripheral blood, CB-T cells
were phenotypically and functionally immature with
major expression of CD45RA, a naïve T cell marker,
and low expression of a marker CD45RO, activated or
memory T cells marker. To confirm antitumor activity
of CB-T cells in vivo,w ef i r s te s t a b l i s h e dam o d e lo f
human cervical cancer by subcutaneously injecting 2 ×
10
6 Caski cervical tumor cells into the flanks of NOD/
SCID mice. Two weeks after these injections, we could
detect palpable tumor formation and growth. We
injected 1 × 10
7 CB mononuclear cells into the tumor
region on the same day or 2 weeks after the injection of
tumor cells. We assessed the antitumor activity of CB
mononuclear cells by measuring the tumor with calipers
on a weekly basis. Mice that were inoculated simulta-
neously with CB mononuclear cells and Caski cells had
complete tumor remission; mice that were inoculated with
CB cells 2 weeks after the tumor-cell injection had marked
antitumor effects compared with control (Figure 1A and
1B). However, mice that received no injection of CB
mononuclear cells had normal tumor progression.
To confirm which CB mononuclear cells type had
antitumor activity, we analyzed the spleen, peripheral
blood, and tumor tissue from the mice inoculated with
tumor and CB mononuclear cells. From flow cytometry
analysis, we found that all mice injected with CB mono-
nuclear cells had only CB-T lymphocytes, CD3
+CD4
+ T
cells, and CD3
+CD8
+ T cells in spleen and tumors; how-
ever, these mice did not have CD19
+ B cells, CD56
+ nat-
ural killer (NK) cells, or CD14
+ myeloid cells (Figure
1C). Immunohistochemical analysis also revealed the
infiltration of CD4
+ Tc e l l sa n dC D 8
+ T cells into
tumor tissue (Figure 1D). The phenotypes of CB T cells
with antitumor activity showed high activation states,
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CD45RO (data not shown). These results indicate that
CD4
+ and CD8
+ T cells from CB have direct antitumor
activity in NOD/SCID mice.
Generation of mature CB-T cells following cord blood
transfer into NOD/SCID mice
In previous assay, we observed the antitumor activity of
CB-derived T cells in a murine model of human cervical
cancer. Fortunately, we established successfully CB-T
reconstituted model mice by an intraperitoneal injection
of 1 × 10
7 CB mononuclear cells into neonatal NOD/
SCID mice. Four weeks after injection, we assessed the
reconstitution of CB-T cells by using flow cytometry to
analyze peripheral blood, spleen, thymus, and bone mar-
row. We observed a high engraftment rate of human
CD45
+ hematopoietic cells in all of these tissues. Interest-
ingly, most of the CD45
+ cells were also CD3
+,b u taf e w
positive for CD19, CD14
+, or CD56
+ (Figure 2A). CD45
+
CD3
+ cells constituted 1.8 ± 1.2% of bone marrow, 14.3 ±
9.4% of thymus, 55.6 ± 21.9% of spleen, and 6.8 ± 3.9% of
peripheral blood at 6 weeks after transplantation (n =6 )
(Table 1). On flow cytometry analysis, T cells were found
to express different combinations of CD3, CD4, CD8,
and TCRab but not CD38 and CD62L. (Figure 2B and
2C). These data indicate the presence of mature T cells
different from native CB-T cells. Histological analysis
revealed that CD4
+ T cells and CD8
+ T cells were present
in the thymus and spleen of mice injected with cord
blood mononuclear cells (Figure 2D).
Cord blood derived T cells inhibit tumor growth in vivo
To assess antitumor activity of CB-T cells in vivo,2×1 0
6
cervical tumor cells (Caski or HeLa) or lung tumor cells
(A549) were subcutaneously injected in the right flank of
mice that either had or had not been previously injected
with CB-T cells. Eight weeks after the tumor-cell injection,
the mice were sacrificed and the volume and weight of the
tumor were determined. The CB-T cells pre-reconstituted
NOD/SCID mice before tumor injection showed
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Figure 1 Cord blood mononuclear cells inhibit tumor growth in human cervical tumor animal model. A, representative tumor formation
at 8 weeks in NOD/SCID mice injected subcutaneously with Caski cells (2 × 10
6 cells) was shown. B, Caski cells (2 × 10
6 cells) were injected
subcutaneously into the posterior region of NOD/SCID mice with 1 × 10
7 human cord blood mononuclear cells on day 0 or day 14 after the
tumor injection. Data are presented on tumor size and weight at 8 weeks, when the animals were sacrificed. * and ** are 0.05. C, Caski tumors
prepared from CB injected NOD/SCID mice were analyzed by flow cytometry with anti-human CD19 and CD3, or CD4 and CD8 antibodies. D,
immunohistochemical analysis of tumors in mice was detected the presence of high level of tumor infiltrated CD8
+ T cells and CD4
+ T cells,
derived from CB mononuclear cells on 0 (left) and 14 (right) days after Caski injections. Hoechst dye was used for counterstaining of cell nuclei.
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Page 4 of 11significant inhibition of tumor growth in both cervical and
lung cancer injected mice, while the control mice without
CB-T cells did not show inhibition of tumor growth (Fig-
ure 3A, B and 3C). Phenotypic analysis of antitumor CD3
+
T cells from spleen, peripheral blood and tumors showed
a majority of CD45RO
+ T cells, but few CD45RA
+ T cells
(Figure 3D). On immunohistochemical analysis, we
observed high numbers of CD8
+ T cells and CD4
+ T cells
near one another in the tumors formed by Caski and
HeLa cervical cancer cells, as well as A549 lung cancer
(Figure 4A). In addition, CD8
+ T cells were present in
high concentrations in both tumor tissues while CD4
+ T
cells were at a much higher concentration in Caski-cell
tumors than in HeLa-cell tumors. From flow cytometry
analysis, we confirmed that a relatively high proportion of
the CD3
+ T cells were present in the hematopoietic organs
of mice that had Caski-cell injections. The TUNEL assay, a
test for apoptotic cells, was highly positive in Caski and
HeLa tumor tissue (Figure 4B). These results suggest that
CB-T cells induced tumor apoptosis directly, resulting in
dramatic tumor remission.
Adoptive immunotherapeutic effects of memory T cells in
vivo
To measure the adoptive immunotherapeutic effects of
CD3
+ T cells, we purified these cells from mice, all of
Figure 2 Reconstitution of human cord blood derived T lymphocytes in NOD/SCID mice. Cord blood mononuclear cells (1 × 10
7 cells) were
injected into the peritoneum of newborn NOD/SCID mice. A, representative flow cytometry data is shown in indicated hematopoietic organs from
NOD/SCID mice injected with cord blood mononuclear cells at 6 weeks after transplantation. B, cells from cord blood or spleen of cord blood
injected NOD/SCID mice were compared the expression of CD38 and CD62L expression in CD3
+ cells. C, splenocytes from cord blood injected
NOD/SCID mice were gated on CD3
+ splenocytes, and analyzed for TCRab expression. D, immunohistochemical analysis of the thymus (left) and
spleen (right) was performed using antibodies to CD4 (FITC) and CD8 (PE). Hoechst dye was used for counterstaining of cell nuclei.
Table 1 The percentage of human hematopoietic cells in
NOD/SCID mice injected with cord blood mononuclear
cells
Cell Types % of human cells in tissues
Bone marrow Thymus Spleen PBL
CD45 2.4 ± 1 81.5 ± 16.5 66.9 ± 9.7 8.4 ± 3.8
CD3 1.8 ± 1.2 14.3 ± 9.4 55.6 ± 21.3 6.8 ± 3.9
CD19 0.1 ± 0.2 11.3 ± 9.9 2.8 ± 4.5 ND
CD33 ND* 0.7 ± 0.4 0.4 ± 0.5 0.2 ± 0.3
CD56 0.1 ± 0.1 1 ± 0.7 0.3 ± 0.3 ND
*ND = not detected.
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called as 2
nd CB-T, or non pre-adopted T cells in mice,
called as 1
st CB-T as control. A total of 1 × 10
6 of each
of CD3
+ T cells were inoculated into the tumor region
of mice that been injected 3 weeks earlier with 2 × 10
6
Caski cells. A group of control mice with Caski cell
tumors that were not injected with purified T cells all
showed progressive tumor growth. In contrast, we
observed a significant decrease in the tumor diameter
and weight in the mice that received injections of Caski
pre-adopted CD3
+ T cells (Figure 5A and 5B) and, to a
lesser extent, in those that received non pre-adopted T
cells. The in vitro cytotoxic activities of the pre-adopted
and non pre-adopted T cells were similar to their in
vivo antitumor effects (data not shown). In tissue analy-
sis, CD4
+ T cells and CD8
+ T cells were detected widely
in the tumors, but the infiltrating activity of the cells
was higher in the recipients of pre-adopted T cells than
non pre-adopted T cells. Both types of T cells, however,
expressed CD45RO, a marker of active and memory T
cells, but no detectable of CD45RA, a marker for naïve
T cells (Figure 5C). To quantify tumor infiltration, we
harvested whole cells from tumor tissue and analyzed
the percentage of CD3
+ T cells. The proportion of CD3
+ T cells was 20.5 ± 3.2% for pre-adopted T cells vs. 12
± 2.3% for non pre-adopted T cells (n =4 ;P < 0.05)
(Figure 5D).
In vitro assay for specific cytotoxic activity
We assessed whether mice with both reconstituted
immunity and inoculation with Caski tumor cells pos-
sessed memory T cells with specific activity against cer-
vical tumor cells in vitro. Purified CD3
+ T cells from
these mice were cocultured with Caski cells, as specific
target cells, and A549 human lung cancer cells, as a
negative control. Cytotoxic effects were then determined
by Annexin V and PI staining with flow cytometry ana-
lysis. The T cells showed significantly higher cytotoxic
activity against Caski cells than against A549 control
cells (Figure 6A). This finding suggests that mice with
reconstituted immunity that are injected with Caski
tumor cells develop memory T cells with specificity for
the tumor cells. We performed an additional in vitro
analysis to assess the tumor-specific cytotoxic activity of
purified CD3
+ T cells from spleen of mice which are
either adapted or non-adapted mice followed by either
Figure 3 Antitumor activity of T lymphocytes to cervical and lung tumors in NOD/SCID mice with and without previously injected
cord blood. A, representative tumors size and weight at 8 weeks after injection with A549 (2 × 10
6 cells) into mice with or without previous
cord blood transfer were shown (* P <0.05). B and C, The size and weight of tumors were measured 8 weeks after subcutaneous injection of
Caski (B) or HeLa (C) cervical cancer cells without and with CB T-cell grafts (* P <0.05). D, phenotype of cells from splenocytes of mice with T-cell
grafts followed by injections with Caski cells; flow cytometry analysis with antibodies to CD3, CD45RO, and CD45RA.
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of tumor cells. We found much higher cytotoxicity in T
cells from tumor adapted T cells bearing mice than T
cells than non-adapted control T cells and peripheral
blood (Figure 6B).
Biological function of tumor antigen specific T cells
To evaluate specific recognition of tumor antigens by
CD8
+ T cells, we assessed whether tumor reactive mem-
ory T cells from mice can react against defined HPV 16
peptides, E711-20 peptide (YMLDLQPETT) and E786-93
Figure 4 T cell infiltration and induction of tumor cell death in cervical and lung tumor tissue. Cervical (Caski and HeLa) and lung (A549)
tumor cells were injected into T cell engrafted NOD/SCID mice. Mice were sacrificed at 8 weeks later, and the remaining tumor was prepared. A,
frozen tumor sections were stained for human CD4 (FITC) and CD8 (PE) from Caski (left), HeLa (middle), and A549(right) (upper panels), CD8
(FITC) and CD45RO (PE) from Caski (left), HeLa (middle), and A549(right) (bottom panels). B, for detecting apoptotic cells, tumors with Caski only
(upper) and Caski with T cells (bottom) (left panels), HeLa only (upper) and HeLa with T cells (bottom) (middle panels), and A549 only(upper)
and A549 with T cells (bottom) (right panels) was investigated with the TUNEL assay. Cell nuclei are indicated with blue fluorescent Hoechst
counterstaining.
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+ T cells purified from Caski
adopted or non-adopted mice were co-cultured with
peptides for 48 hr. We measured the production of
interferon-gamma (IFN-g) by ELISPOT assay. The pro-
portion of IFN-g-producing memory T cells among total
T cells from Caski adopted T cells was markedly higher
(P <0.05) than among T cells from non-adopted T cells
(Figure 6C).
Discussion
There are several reports that allogeneic or autologous
lymphocytes from peripheral blood and bone marrow
have been used in antitumor immunotherapy [14,25]. In
contrast, cord blood has been used mainly as a substi-
tute source in allogeneic bone marrow stem cell trans-
plantation, because of its low graft-versus-host activity,
which is attributed to the immaturity of the lympho-
cytes. The immunotherapeutic potential of cord blood
in general, and NK and dendritic cells in particular,
have been studied in several hematological malignances
and solid tumors [26,27]. Here we provide direct evi-
dence, in an animal model of cervical cancer, of the
antitumor activity of T cells derived from cord blood.
We also found in vitro evidence of cytotoxic activity
specific to tumor antigens.
First, we found that CB mononuclear cells showed
immunotherapeutic effects against human cervical
t u m o ri nN O D / S C I Dm i c et h a tw e r ee i t h e rs i m u l t a -
neously or previously injected with tumor cells. These
mice showed, respectively, complete or incomplete but
significant tumor remission. The flow cytometry and
immunohistochemical staining of tumors revealed
Figure 5 Adoptive T-cell transplantation enhances antitumor activity in vivo.N O D / S C I Dm i c ew i t hp r i o rc o r db l o o dTc e l l( C B - T )
reconstitution by neonatal injections were given either no inoculation or an inoculation with Caski cells. T cells were then purified from the
tumor non-adopted (1
st CB-T) or pre-adopted (2
nd CB-T) splenocytes of these mice and injected at a dose of 1 × 10
6 T cells into tumors in NOD/
SCID mice that had Caski cell injections 4 weeks earlier. A, tumors from each mouse at 4 weeks after the injection of T cells. B, compared to
non-adoptive T cells, adoptive T cells induced a dramatic inhibition of tumor growth (* P < 0.05, ** P <0.01). C, immunostaining of T cells
infiltrated tumor tissue treated with 1
st CB-T cells in tumor mice (left panels) or 2
nd adoptive CB-T cells (right panels) in Caski tumor mice.
Sections were stained for CD8 (green) and CD4 (red) (upper panels), or CD8 (green) and CD45RO (red)(bottom panels). × 200. Hoechst dye was
used for counterstaining of cell nuclei. D, tumor cells from control mice (with Caski tumors but no T cell injection), 1
st CB-T mice, and 2
nd CB-T
mice were investigated with CD3 staining using flow cytometry.
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+ and CD8
+ T
cells. These cells had a mature phenotype, CD45RO
+
but CD45RA
-, which differs from the phenotype of
native CB T cells. Therefore, we concluded that mature
T cells derived from CB could be useful as allogeneic
antitumor immunotherapeutic cells, likely of as are T
cells from peripheral blood and bone marrow.
Meanwhile, we established the optimal animal model
for maturation and differentiation of CB-T cells in
NOD/SCID mice by intraperitoneal injection of new-
born mice without any pre-treatment of the cells with
irradiation or TM-b1. Several trials have been conducted
to reconstitute T lymphocytes in animal models using
NOD/SCID mice and NOD/SCID/gc
null mice with puri-
fied CD34
+ cells from cord blood and bone marrow
[26,28,29]. From these studies, NOD/SCID mice showed
very low efficiency for reconstitution of T lymphocytes.
In our system, however, the reconstituted T cells from
cord blood appeared capable of undergoing continuous
proliferation and differentiation. Thus, the mice main-
tained a stable, mature population of T cells, such as
CD3
+CD4
+ T cells and CD3
+CD8
+ T cells with TCRab
and CD45RO expression, but not CD45RA expression
on the cell surface. These cells were found in several
hematopoietic organs, such as spleen, peripheral blood,
thymus, and lymph nodes. We found that CD3
+CD38
+
T progenitor cells could differentiate into mature T lym-
phocytes based on evidence comparing the transplantation
of CD34
+ cells and CD3
+CD38
+ cells from CB into new-
born NOD/SCID mice. We confirmed that CD3
+CD38
+
progenitor cells developed into CD3
+CD38
- mature T
cells, even when engraftment efficiency was relatively low,
but CD34
+ cells was not observed such a maturation in
neonatal injected NOD/SCID mice (data not shown).
Figure 6 Cytotoxic activity and detection of cervical tumor specific T cells. A, cervical tumor specific cytotoxic activity was shown. T cells
were purified from splenocytes of NOD/SCID mice inoculated with cord blood T cells (CB-T) and Caski tumor cells. The T cells were cocultured
with Caski cells, HeLa cells, or A549 cells (human lung cancer cells) as a negative control. Cytotoxicity was tested by flow cytometry with several
effector-to-target ratios. B, cytotoxic activity of purified T cells against HeLa (left) and Caski (right) cells was determined for non-adoptive T cells
(1
st CB-T) and adoptive T cells (2
nd CB-T), and human peripheral blood T lymphocytes (PBL-T) as a control. Each bar indicates the mean ± S.D. as
determined from the average of quadruplicate wells (* P < 0.01). C, ELISPOT assay for interferon-gamma (INF-g) production was conducted with
E711-20 peptide (YMLDLQPETT) and E786-93 peptide (TLGIVCPI) HPV specific peptides with non-adopted T cells and adopted T cells. Each bar
represents the mean ± S.D. as determined (* P < 0.05).
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Page 9 of 11In a biological activity assay, mature T cells obtained
from NOD/SCID mice that received CB transplants
showed slightly higher cytotoxic activity and prolifera-
tion capacity than PB-T cells (Figure 6B and 6C), as
well as in response to treatment with IL-2 and mitogen
(data not shown). This finding suggests that mature T
cells from cord blood may preserve a potential for biolo-
gical activity that is higher than that of PB-T cells.
A key aspect of our finding was the specificity of the
observed antitumor activity by mature T lymphocytes
derived from CB. Because cervical cancer is well charac-
terized, cancer, we used two representative cell lines,
Caski (HPV-16 type) and HeLa (HPV-18 type), to test T
cells specific recognition and reactivity against tumor
antigens. For example, E6 and E7 proteins in HPV were
used as specific indicators and markers for identifying T
lymphocytes with cervical tumor specificity [30-32].
From the antitumor activity assay using pre-established
T lymphocytes from CB, we confirmed, by ELISPT assay
and HPV-tetramer analysis that these T cells had speci-
ficity for cervical tumor antigens. This specificity
resulted in significant inhibition of tumor growth in in
vivo and cytotoxic activity in vitro. In an adoptive trans-
fer assay, specifically activated T cells greatly infiltrated
the cervical tumor area. These cells were associated with
a much greater inhibition of tumor progression than
were primary cord blood mature T cells. Significantly
stronger GVT effects were observed with T cells pre-sti-
mulated to cervical tumor, as evidenced by significant
tumor inhibition and a dense infiltration of T cells in
the tumor area. From immunohistochemical assay,
human CD4
+ and CD8
+ Tc e l l si n f i l t r a t e di nt u m o r
were closely associated with antitumor effects and
tumor apoptosis. The TUNEL assay suggested that the
mechanism of tumor remission by CB-T cells was
mediated through Fas related apoptosis in tumor tissue,
because Fas was expressed on the cell surface of both
cervical tumor cells used in this study.
I nas u b s e q u e n tn e x ti n v e s t i g a t i o n ,w ec o m p a r e dt h e
antitumor activity of peripheral blood derived T cells,
native cord blood T cells, and mature cord blood T cells
purified from NOD/SCID mice. We confirmed that CD3
+
T cells from mature cord blood in NOD/SCID mice
showed a relatively higher antitumor activity than T cells
from either peripheral blood or native cord blood (unpub-
lished data). There are several reports on the molecular,
phenotypic, and functional differences in T cells from per-
ipheral blood and cord blood [6,33-35], but the differences
in functional activity between mature T cells from cord
blood and peripheral blood are not yet known. In particu-
lar, antitumor effects warrant further investigation because
of their potential impact on immunotherapeutic
approaches to cancer. It is essential to develop techniques
that promote the differentiation and proliferation of CB T
cells into cells with more efficient antitumor cytotoxicity.
Such techniques may involve coculture with tumor anti-
gens and tumor lysates, followed by expansion of tumor
specific T cells with high proliferative ability. It is also
essential to establish more reliable and effective systems
for growing and differentiating CB-T cells and hemato-
poietic stem cells into mature T cells that can be used for
clinical immunotherapy.
Conclusions
We demonstrated that mature T cells derived from CB
exhibit potent antitumor effects in an animal model of
human cervical cancer. These antitumor effects resulted
from the induction of tumor-specific CD8
+ Tc e l l sa n d
CD4
+ T cells that recognized cervical tumor antigens.
Our data provide evidence that cord blood has a great
potential not only in bone marrow transplantation but
also in immunotherapy used to treat various neoplasms.
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